Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena, Maria Di Bartolomeo, Kanwal P. S. Raghav et al. · The Lancet Oncology · 2021
Cited by 422 works. doi:10.1016/s1470-2045(21)00086-3
Authors
- Salvatore Siena
- Maria Di Bartolomeo
- Kanwal P. S. Raghav
- Toshiki Masuishi
- Fotios Loupakis
- Hisato Kawakami
- Kensei Yamaguchi
- Tomohiro Nishina
- Marwan Fakih
- Elena Élez
- Javier Rodríguez
- Fortunato Ciardiello
- Yoshito Komatsu
- Taito Esaki
- Ki Young Chung
- Zev A. Wainberg
- Andrea Sartore Bianchi
- Kapil Saxena
- Eriko Yamamoto
- Emarjola Bako
References
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- Comprehensive review of targeted therapy for colorectal cancer
- Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS